Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology

被引:157
作者
Garcovich, Simone [1 ]
Colloca, Giuseppe [2 ]
Sollena, Pietro [1 ]
Bellieni, Andrea [2 ]
Balducci, Lodovico [3 ]
Cho, William C. [4 ]
Bernabei, Roberto [2 ]
Peris, Ketty [1 ]
机构
[1] Univ Cattolica Sacro Cuore, Policlin A Gemelli Univ Hosp, Inst Dermatol, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Policlin A Gemelli Univ Hosp, Dept Geriatr, Rome, Italy
[3] H Lee Moffitt Canc Ctr & Res Inst, Senior Adult Oncol Program, Tampa, FL USA
[4] Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China
关键词
skin cancer; elderly cancer patients; geriatrics; basal cell carcinoma; squamous cell carcinoma; melanoma; geriatric assessment; disease management; BASAL-CELL CARCINOMA; QUALITY-OF-LIFE; MOHS MICROGRAPHIC SURGERY; LYMPH-NODE BIOPSY; AGED; 90; YEARS; OLDER PATIENTS; UNITED-STATES; RISK-FACTORS; DERMATOLOGICAL SURGERY; CUTANEOUS MELANOMA;
D O I
10.14336/AD.2017.0503
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Skin cancer is a worldwide, emerging clinical need in the elderly white population, with a steady increase in incidence rates, morbidity and related medical costs. Skin cancer is a heterogeneous group of cancers comprising cutaneous melanoma and non-melanoma skin cancers (NMSC), which predominantly affect elderly patients, aged older than 65 years. Melanoma has distinct clinical presentations in the elderly patient and represents a challenging question in terms of clinical management. NMSC includes the basal cell carcinoma and cutaneous squamous cell carcinoma and presents a wide disease spectrum in the elderly population, ranging from low-risk to high-risk tumours, advanced and inoperable disease. Treatment decisions for NMSC are preferentially based on tumour characteristics, patient's chronological age and physician's preferences and operational settings. Several treatment options are available for NMSC, from surgery to non-invasive/medical therapies, but patient-based factors, such as geriatric comorbidities and patient's life expectancy, do not frequently modulate treatment goals. In melanoma, age-related variations in clinical management are significant and may frequently lead to under-treatment, limiting access to advanced surgical and medical treatments. Clinical decision-making in the care of elderly skin cancer patient should ideally implement a geriatric assessment, prioritizing patient-based factors and efficiently differentiating fit from frail cancer patients. Current clinical practice guidelines for NMSC and melanoma only partially address geriatric aspects of cancer care, such as frailty, limited life-expectancy, geriatric comorbidities and treatment compliance. We review the recent evidence on the scope and problem of skin cancer in the elderly population as well as age-related variations in its clinical management, highlighting the potential role of a geriatric approach in optimizing dermato-oncological care.
引用
收藏
页码:643 / 661
页数:19
相关论文
共 132 条
[41]   Life expectancy after Mohs micrographic surgery in patients aged 90 years and older [J].
Delaney, Amy ;
Shimizu, Ikue ;
Goldberg, Leonard H. ;
MacFarlane, Deborah F. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (02) :296-300
[42]   Non-melanoma skin cancer treated with high-dose-rate brachytherapy and Valencia applicator in elderly patients: a retrospective case series [J].
Delishaj, Durim ;
Laliscia, Concetto ;
Manfredi, Bruno ;
Ursino, Stefano ;
Pasqualetti, Francesco ;
Lombardo, Ezio ;
Perrone, Franco ;
Morganti, Riccardo ;
Paiar, Fabiola ;
Fabrini, Maria Grazia .
JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2015, 7 (06) :437-444
[43]   Iatrogenic immunosuppression and cutaneous malignancy [J].
DePry, Jennifer L. ;
Reed, Kurtis B. ;
Cook-Norris, Robert H. ;
Brewer, Jerry D. .
CLINICS IN DERMATOLOGY, 2011, 29 (06) :602-613
[44]   No End in Sight: The Skin Cancer Epidemic Continues [J].
Donaldson, Matthew R. ;
Coldiron, Brett M. .
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2011, 30 (01) :3-5
[45]   Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].
Eggermont, A. M. M. ;
Chiarion-Sileni, V. ;
Grob, J. -J. ;
Dummer, R. ;
Wolchok, J. D. ;
Schmidt, H. ;
Hamid, O. ;
Robert, C. ;
Ascierto, P. A. ;
Richards, J. M. ;
Lebbe, C. ;
Ferraresi, V. ;
Smylie, M. ;
Weber, J. S. ;
Maio, M. ;
Bastholt, L. ;
Mortier, L. ;
Thomas, L. ;
Tahir, S. ;
Hauschild, A. ;
Hassel, J. C. ;
Hodi, F. S. ;
Taitt, C. ;
de Pril, V. ;
de Schaetzen, G. ;
Suciu, S. ;
Testori, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855
[46]   Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies [J].
Eggermont, Alexander M. M. ;
Maio, Michele ;
Robert, Caroline .
SEMINARS IN ONCOLOGY, 2015, 42 (03) :429-435
[47]   Immune Checkpoint Inhibitors in Older Adults [J].
Elias, Rawad ;
Morales, Joshua ;
Rehman, Yasser ;
Khurshid, Humera .
CURRENT ONCOLOGY REPORTS, 2016, 18 (08)
[48]  
Ellis BH, 2004, HEALTH CARE FINANC R, V25, P75
[49]  
Fayers PM., 2007, Quality of life the assessment, analysis, and interpretation of patientreported outcomes, V2nd
[50]   DERMATOLOGY LIFE QUALITY INDEX (DLQI) - A SIMPLE PRACTICAL MEASURE FOR ROUTINE CLINICAL USE [J].
FINLAY, AY ;
KHAN, GK .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1994, 19 (03) :210-216